Data are available in accordance with the Whitehall II data sharing policy: <https://www.ucl.ac.uk/whitehallII/data-sharing>.

Introduction {#sec001}
============

Uncoupling protein (UCP) 2 is a proton carrier found in the inner mitochondrial membrane. It is responsible for uncoupling electron transport through the electron transfer chain from the active pumping of protons across the inner mitochondrial membrane, thus uncoupling electron transport from adenosine triphosphate (ATP) formation \[[@pone.0181392.ref001]\]. UCP2 is abundantly expressed in brain tissue and in non-human primates it can be found in areas, such as the hypothalamic nuclei, pituitary gland, brainstem (incl. raphe nucleus and locus coeruleus), ventral tegmental area and substantia nigra \[[@pone.0181392.ref002]\]. There are few investigations of UCP2 expression in the human brain but expression has been shown in the cortex and basal ganglia with increased expression in the periphery of ischemic stroke lesions \[[@pone.0181392.ref003]\]. It affects neuronal function in multiple ways, e.g. as a regulator of production of reactive oxygen species (ROS) \[[@pone.0181392.ref004]\]. Thus UCP2 provides a plausible link between mitochondrial (dys-)function, ROS production, ageing and neurodegeneration \[[@pone.0181392.ref005]\]. For example, UCP2 overexpression in mice protects neurons in the substantia nigra of a Parkinson's disease model \[[@pone.0181392.ref006]\]. UCP2 also appears to play a role in neuronal plasticity and regeneration \[[@pone.0181392.ref007]\], and human UCP2 expression extends the lifespan of flies and mice \[[@pone.0181392.ref008]\].

There are several polymorphisms of the *UCP2* gene in humans. The most frequently investigated polymorphisms are the -866G\>A promoter polymorphism, which affects *UCP2* mRNA expression, and the Ala55Val polymorphism in the exon of the gene leading to a substitution of amino acids, which affects the degree of uncoupling and thus protein function \[[@pone.0181392.ref004]\]. Some studies have shown links between these polymorphisms and risk of obesity, insulin resistance and diabetes \[[@pone.0181392.ref009]\], although there are many conflicting reports on these effects \[[@pone.0181392.ref010]\]. A study that investigated the effects of *UCP* gene variants on longevity found that *UCP2* polymorphisms affect survival into old age \[[@pone.0181392.ref011]\].

Due to the potential link between *UCP2* gene variants, ROS production and longevity, we investigated in this study, whether *UCP2* polymorphisms affect the risk of developing neurodegenerative diseases and whether they account for any variance in brain structure or function.

We examined data from the Whitehall II imaging sub-study. Whitehall II is an ongoing epidemiological study that has followed-up an initial cohort of 10,000 British civil servants since 1985, with the aim of advancing knowledge of the causal chain through which social circumstances influence health \[[@pone.0181392.ref012]\]. Over the past 30 years a wealth of social, behavioural and biological data have been acquired, which makes Whitehall II a unique study of ageing. Within the Whitehall II imaging sub-study brain magnetic resonance imaging (MRI) scans of 800 participants randomly selected from the original Whitehall II study of 10,308 British civil servants were acquired \[[@pone.0181392.ref013]\]. In the study presented here, data from 563 individuals aged 60 to 83 years that have been scanned prior to January 2016 were analyzed.

We investigated effects of *UCP2* polymorphisms on risk of neurodegenerative disease (defined as having a clinical diagnosis of Parkinson's disease, Alzheimer's disease, mild cognitive impairment (MCI), stroke, transient ischemic attack or multiple sclerosis) and the risk of having a lifetime diagnosis of mental health disorder (defined as current or past episodes of mood disorders or anxiety disorders) in this sample. To determine effects of *UCP2* polymorphisms on brain structure and function, we investigated grey and white matter structure, as well as functional brain connectivity at rest, using structural, diffusion and functional MRI.

Material and methods {#sec002}
====================

Participants {#sec003}
------------

In order to make the Whitehall II neuroimaging sub-sample as representative as possible of the cohort at baseline, a random sample of 800 Whitehall II Phase 11 participants willing and able to give informed consent were invited to attend the imaging sub-study at the Oxford Centre for Functional MRI of the Brain (FMRIB). To achieve a sufficient number of participants with depression, we enriched the sample by 30 participants with depressive symptoms based on previous Whitehall II clinical examinations. We excluded participants with contraindications to MRI scanning (including but not limited to a history of claustrophobia, certain metallic implants and metallic injury to the eye), or who were unable to travel to Oxford without assistance. Data from 563 individuals aged 60 to 83 years that have been scanned prior to January 2016 were included in the analyses.

Ethical approval for the Whitehall II study was obtained from the University College London Medical School committee on the ethics of human research and all participants provided written informed consent. Ethical approval for neuroimaging data acquisition was granted generically for the "Protocol for non-invasive magnetic resonance investigations in healthy volunteers" (MSD/IDREC/2010/P17.2) by the University of Oxford Central University/ Medical Science Division Interdisciplinary Research Ethics Committee (CUREC/ MSD-IDREC), who also approved the specific protocol: "Predicting MRI abnormalities with longitudinal data of the Whitehall II sub-study" (MSD-IDREC-C1-2011-71, PI: KPE). The Health Research Authority NRES Committee South Central---Oxford C approved the study: "Biological mechanisms and risk factors in late onset depression" (REC Reference: 10/H0606/71, PI: CLA) that allowed us to examine participants with a past history of depressive symptoms.

The study follows the Medical Research Council (MRC) Policy on data sharing, i.e. images and other data will be available for analysis by other groups after completion of the study, as is the case with the Whitehall II study (see <http://www.ucl.ac.uk/whitehallII/data-sharing>).

Clinical and cognitive assessment {#sec004}
---------------------------------

Each participant recruited for the Whitehall II imaging sub-study underwent a detailed clinical and cognitive assessment lasting up to two hours. The clinical assessment consisted of a (A) self-administered questionnaire, a (B) semi-structured clinical interview and (C) cognitive assessment. For this study only a subset of the data was used, which is described here in more detail. For an overview of all assessments, please see \[[@pone.0181392.ref013]\].

1.  \- General Health Questionnaire-30 (GHQ-30 \[[@pone.0181392.ref014]\]): The GHQ-30 is a 30-item self-administered screening questionnaire for the detection of psychiatric illness in non-psychiatric clinical and community settings.

2.  \- Montreal Cognitive Assessment (MoCA \[[@pone.0181392.ref015]\]): The MoCA is a 30-point cognitive screening test assessing multiple cognitive domains: visuo-spatial abilities, short-term memory recall, executive function, attention, orientation and working memory, language and orientation to time and space.

3.  \- Centre for Epidemiological Studies Depression Scale (CES-D \[[@pone.0181392.ref016]\]): The CES-D is short self-report scale that measures major depressive symptomatology in the general population.

4.  \- Test of Premorbid Functioning (TOPF \[[@pone.0181392.ref017]\]): The TOPF consists of a list of seventy written words, which must be read aloud and is marked according to pronunciation. The TOPF is used to estimate an individual\'s level of intellectual functioning before the onset of injury or illness. Premorbid IQ can be calculated from the raw score, adjusted for sex and years of education.

5.  \- Structured Clinical Interview for DSM-IV-TR Axis I Disorders \[[@pone.0181392.ref018]\]: The SCID-I is a semi-structured interview for diagnosing current and past DSM-IV Axis I disorders and is administered by a trained graduate psychologist or psychiatrist.

Genotyping {#sec005}
----------

DNA was extracted from whole blood samples (via magnetic bead technology; Medical Solutions, Nottingham, UK) and normalized to a concentration of 50 ng/μl. Participants were genotyped for two polymorphisms of the *UCP*2 gene, -866G\>A (rs659366) and Ala55Val (rs660339) using SNPLex (Applied Biosciences, Inc., Warrington, United Kingdom) by Medical Solutions Plc (Nottingham, United Kingdom)\[[@pone.0181392.ref019]\].

Neuroimaging data acquisition {#sec006}
-----------------------------

A detailed description of the image acquisition protocols and pre-processing steps for neuroimaging data can be found in \[[@pone.0181392.ref013]\]. In brief, scanning was carried out at FMRIB using a 3 T Siemens Magnetom Verio (Erlangen, Germany) Scanner with a 32-channel receive head coil. The neuroimaging protocol comprised both structural and functional sequences and lasted approximately 50 minutes. The MRI sequences that were analyzed for this study included high-resolution T1-weighted MRI (multi-echo MPRAGE \[[@pone.0181392.ref020]\], TR = 2530 ms, TE = 1.79/3.65/5.51/7.37 ms, flip angle = 7°, field of view = 256 mm, voxel dimension = 1 mm isotropic, acquisition time = 6 min 12 s), diffusion MRI (dMRI) (TR = 8900 ms, TE = 91.2 ms, field of view = 192 mm, voxel dimension = 2 mm isotropic, B-value = 1500 s/mm^2^, gradients applied = 60 isotropically distributed diffusion-weighted directions with b-value = 1500 s/mm^2^, 5 non-diffusion weighted images, b-value 0s/mm^2^, with one b0 volume acquired in the reversed phase encoded direction, acquisition time = 9 min 56 s) and resting-state functional MRI (rsfMRI) (multiband echo-planar imaging, TR = 1300 ms, TE = 40 ms, flip angle = 66°, field of view = 212 mm, voxel dimension = 2 mm isotropic, acquisition time = 10 min 10 s). For the rsfMRI scan subjects were instructed to lie in dimmed light with their eyes open, blink normally, but not to fall asleep.

Neuroimaging data pre-processing {#sec007}
--------------------------------

For neuroimaging data pre-processing we used standard FMRIB Software Library (FSL) tools v5.0 (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/>) \[[@pone.0181392.ref021]\]. A detailed description of the data pre-processing steps can be found in \[[@pone.0181392.ref013]\]. The pre-processing pipeline for T1-weighted images included: re-orientating images to the standard (MNI) template, bias field correction, registration to the MNI template using both linear (FLIRT) and non-linear (FNIRT) registration tools and brain extraction. Brain tissues were segmented using FMRIB\'s Automated Segmentation Tool (FAST) that allows extracting measures of total grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF) \[[@pone.0181392.ref022]\]. Brain tissues and sub-cortical regions were visually inspected to ensure an accurate segmentation, and manually edited where necessary.

The pre-processing pipeline for diffusion MRI data used a recently developed approach that simultaneously considers and corrects for susceptibility-induced distortions, eddy-currents and head motion, which is based on methods developed and applied to the Human Connectome Project (HCP) diffusion MRI data \[[@pone.0181392.ref023]\]. Fractional anisotropy (FA), mean diffusivity (MD), axial (DA) and radial diffusivity (DA) maps were generated using DTIFit, part of FMRIB's Diffusion Toolbox, that fits a diffusion tensor model at each voxel \[[@pone.0181392.ref024]\].

Resting-state fMRI data pre-processing consisted of motion correction, brain extraction, high-pass temporal filtering with a cut-off of 100 s, and field-map correction and was carried out using FSL Multivariate Exploratory Linear Optimized Decomposition into Independent Components (MELODIC) \[[@pone.0181392.ref025]\]. To identify and regress out the "signal" of artefactual components reflecting non-neuronal fluctuations, we used single-subject independent component analysis (ICA) followed by an automatic component classification with FMRIB\'s ICA-based X-noiseifier (FIX) \[[@pone.0181392.ref026], [@pone.0181392.ref027]\]. The pre-processed and "cleaned" functional data was registered to the individual\'s structural scan and standard space images using FNIRT, then optimized using boundary-based-registration approach \[[@pone.0181392.ref028]\], and finally spatially smoothed using an isotropic Gaussian kernel of 6 mm full width at half maximum (FWHM).

Neuroimaging data analysis {#sec008}
--------------------------

For data analysis we used standard FSL tools v5.0.

To study grey matter (GM) morphology, the T1-weighted structural imaging data were analysed using a voxel-based morphometry (VBM) approach. Whole-brain analysis was carried out with FSL-VBM \[[@pone.0181392.ref029]\], using default settings.

FMRIB's Integrated Registration and Segmentation Tool (FIRST \[[@pone.0181392.ref030]\]), an automated model-based segmentation/registration tool, was applied to extract volumes of sub-cortical GM structures. Volumes were normalized to total intracranial volume and imported into SPSS for further statistical analyses.

White matter integrity (FA, MD, DA and DR) was analysed using FMRIB's Diffusion Toolbox and tract-based spatial statistics (TBSS), a voxelwise approach for analysis of FA (and MD, DA, DR) data \[[@pone.0181392.ref031]\].

Functional connectivity was analysed using the FSL dual regression method \[[@pone.0181392.ref032]\]. Connectivity of 8 standard resting-state networks defined by a group ICA using MELODIC was analysed: the default-mode network, executive control network, two visual networks, the auditory and sensory-motor networks and left and right fronto-parietal networks \[[@pone.0181392.ref025]\].

For all image-based analyses (VBM, TBSS, dual regression) voxelwise general linear modelling (GLM) was applied using permutation nonparametric testing (5000 permutations) and P\<0.05 correcting for multiple comparisons across space using threshold-free cluster enhancement (TFCE) \[[@pone.0181392.ref033]\]. Three *UCP*2 haplotype groups were compared in this model. Due to the significant effects of *UCP*2 polymorphisms on lifetime risk of mood disorders in men in this sample, we carried out two different analyses of the neuroimaging data. In the first analysis, all participants were included irrespective of sex and lifetime occurrence of mood disorder. One-way ANOVAs were performed to determine *UCP2* haplotype group effects on imaging measures and post-hoc tests were performed to compare means between the three groups. In the second analysis, we only included male participants and investigated main effects of *UCP2* haplotype and lifetime occurrence of mood disorders and their interaction on brain structure and function using a two-way ANOVA. Age was used as a covariate of no interest in all analyses.

Non-image based statistics {#sec009}
--------------------------

We used SPSS software version 23 (SPSS Inc., Chicago, USA) for non-image-based statistical analyses and to compare volumes of subcortical structures. χ^2^ tests were used to compare allelic distributions and determine Hardy-Weinberg equilibrium as well as to compare categorical variables between the three *UCP*2 haplotype groups. Gene-dose effects were analyzed using Mantel-Haenszel linear-by-linear association χ^2^ tests. Linkage disequilibrium between the two *UCP*2 polymorphisms was determined using the online tool CubeX \[[@pone.0181392.ref034]\] (<http://www.oege.org/software/cubex/>). One-way ANOVAs and post-hoc tests with Bonferroni correction were used to compare continuous sociodemographic variables and subcortical volumes between haplotype groups. An alpha of P\<0.05 was considered significant but adjusted for multiple comparison if necessary using Bonferroni correction (alpha was divided by the number of comparisons).

Results {#sec010}
=======

Frequencies of *UCP*2 polymorphisms {#sec011}
-----------------------------------

Genotype data were available for 436 of the 563 individuals included in this analysis. Overall, the observed *UCP* genotype frequencies were in Hardy-Weinberg equilibrium (*p* = 0.62 for -866G\>A and *p* = 0.57 for Ala55Val, [Table 1](#pone.0181392.t001){ref-type="table"}) with values that are similar to those found in the 1000 genomes project (*p* = 0.59 for -866G\>A and *p* = 0.58 for Ala55Val). The two polymorphisms showed strong linkage disequilibrium with D' = 0.99 and r^2^ = 0.80.

10.1371/journal.pone.0181392.t001

###### Comparisons of allelic distributions across the whole sample and between participants with and without mental health disorders.

![](pone.0181392.t001){#pone.0181392.t001g}

                            Whole sample   Male   Female                                                                
  ------------------------- -------------- ------ -------- ------ ------ ------ ------ ----------- ------ ------ ------ ------
  **n**                     436            137    299             359    101    258                77     36     41     
  **G(−866)A (rs659366)**                                  0.07                        **0.013**                        0.30
  **G/G**                   0.38           0.33   0.40            0.38   0.28   0.41               0.39   0.47   0.32   
  **G/A**                   0.48           0.48   0.48            0.48   0.51   0.47               0.48   0.39   0.56   
  **A/A**                   0.14           0.19   0.11            0.14   0.21   0.11               0.13   0.14   0.12   
  **MAF (−866)A**           0.38           0.43   0.36            0.38   0.47   0.35               0.37   0.33   0.40   
  **Ala55Val (rs660339)**                                  0.08                        **0.007**                        0.49
  **C/C**                   0.32           0.26   0.35            0.31   0.20   0.36               0.35   0.42   0.29   
  **C/T**                   0.51           0.53   0.50            0.52   0.56   0.50               0.48   0.42   0.54   
  **T/T**                   0.17           0.22   0.15            0.17   0.24   0.15               0.17   0.17   0.17   
  **MAF 55Val**             0.43           0.48   0.40            0.43   0.52   0.40               0.41   0.38   0.44   

MAF: minor allele frequency, MHD: mental health disorder, P values are based on χ^2^ tests, significant P values are shown in bold.

Effect of *UCP*2 polymorphisms on occurrence of neurodegenerative or mental health disorders {#sec012}
--------------------------------------------------------------------------------------------

*UCP*2 polymorphisms did not significantly affect occurrence of neurodegenerative diseases in this sample. Occurrence of neurodegenerative disease was defined as having a clinical diagnosis of Alzheimer's disease, Parkinsons's disease, stroke, transient ischaemic attack, multiple sclerosis or mild cognitive impairment (based on clinical diagnosis or a MoCA score \< 26). There was a non-significant trend to an overrepresentation of the minor alleles in participants with current or past diagnosis of mental health disorders, according to the SCID (χ^2^(2, n = 436) = 5.27, P\<0.1 for -866A and χ^2^(2, n = 436) = 5.18, P\<0.1 for 55Val) ([Table 1](#pone.0181392.t001){ref-type="table"}). To study possible gender effects, we investigated male and female populations separately. The overrepresentation of both minor alleles was only significant in male participants (χ^2^~(2,436)~ = 8.67, P\<0.05 for -866A and χ^2^(2, n = 436) = 9.94, P\<0.01 for 55Val) but not in female participants ([Table 1](#pone.0181392.t001){ref-type="table"}).

For the G(-866)A polymorphism, there was a higher risk of having current or past diagnosis of mental health disorder for men who carried one (OR = 1.63, 95% CI = 0.96--2.76) or two minor alleles (OR = 2.77, 95% CI = 1.38--5.57) compared with homozygotes for the major allele ([Table 2](#pone.0181392.t002){ref-type="table"}). For the Ala55Val polymorphism there was a higher risk of having current or past diagnosis of mental health disorder for men who carried one (OR = 2.05, 95% CI = 1.15--3.64) or two minor alleles (OR = 2.91, 95% CI = 1.44--5.87) compared with homozygotes for the major allele ([Table 2](#pone.0181392.t002){ref-type="table"}). The gene-dose effect was significant for both polymorphisms (χ^2^(1, n = 359) = 8.56, P\<0.01 for -866A and χ^2^(1, n = 359) = 9.64, P\<0.01 for 55Val).

10.1371/journal.pone.0181392.t002

###### Comparisons of risk and odds between the genotypes in men.

![](pone.0181392.t002){#pone.0181392.t002g}

                            Total (n)   MHD (n)   No MHD (n)   RE     RR     OE     OR
  ------------------------- ----------- --------- ------------ ------ ------ ------ -------------------
  **G(−866)A (rs659366)**                                                           
  **G/G**                   135         28        107          0.21   1      0.26   1
  **G/A**                   174         52        122          0.30   1.44   0.43   1.63 (0.96--2.76)
  **A/A**                   50          21        29           0.42   2.03   0.72   2.77 (1.38--5.57)
  **Ala55Val (rs660339)**                                                           
  **C/C**                   112         20        92           0.18   1      0.22   1
  **C/T**                   185         57        128          0.31   1.73   0.45   2.05 (1.15--3.64)
  **T/T**                   62          24        38           0.39   2.17   0.63   2.91 (1.44--5.87)

MHD: mental health disorder, RE: risk estimates, RR: risk ratios (compared with homozygotes for major allele), OE: odds estimates, OR: odds ratios compared with homozygotes for major allele (with 95% confidence interval in brackets).

We then investigated whether specific diagnoses were overrepresented in those who carried one or two minor alleles of the two polymorphisms. 97 out of 101 participants who reported current or past episodes of mental health disorders suffered from mood disorders (defined as bipolar disorder, dysthymic disorder, recurrent or single episode major depressive disorder and unspecified mood disorders, which includes minor depression). The numbers for each of the disorders were insufficient to conduct any further statistical analyses.

We sought to replicate this effect in a larger Whitehall II sample of 5025 participants who took part in phase 9 (data collected from 2007--2009) and were genotyped for *UCP2*. However, there was no SCID data available for these participants. Therefore, participants were classified as having a current or past episode of mood disorder according to a definition used in previous Whitehall II studies \[[@pone.0181392.ref035]\]: a total score of 5 or more on the GHQ, a total score of 16 or more on the CES-D and the use of antidepressant medication in any of the previous Whitehall II phases. Using this metric, we were not able to replicate the significant effect of *UCP2* polymorphisms on occurrence of mood disorders in the larger sample.

Neuroimaging data analysis of haplotype groups {#sec013}
----------------------------------------------

Due to the strong linkage disequilibrium between the two *UCP2* polymorphisms, participants were grouped according to three different haplotype groups for all analyses of neuroimaging data: homozygotes for the major alleles (called haplotype group 1 (HT1)), homozygotes for minor alleles (HT3), and heterozygotes (HT2). Out of the 436 participants included in this analysis, 317 participants fell into one of these three groups and had complete neuroimaging datasets available. There were 112 participants in HT group 1, 155 in HT2 and 50 in HT3. These groups did not show any differences in socio-demographic variables (age, years of education, MOCA score, IQ or body-mass index (BMI), [Table 3](#pone.0181392.t003){ref-type="table"}). Although the sex distribution in this sample is representative of the overall Whitehall II sample in that around 80% of all participants are male, the three haplotype groups did not significantly differ in sex distributions.

10.1371/journal.pone.0181392.t003

###### Comparisons of socio-demographic variables between the haplotype groups included in the neuroimaging analysis.

![](pone.0181392.t003){#pone.0181392.t003g}

                                 HT1 (GG/CC)   HT2 (GA/CT)    HT3 (AA/TT)   P Value
  ------------------------------ ------------- -------------- ------------- ---------
  **n**                          112           155            50            
  **Age**                        69.7 (5.4)    69.3 (5.4)     69.9 (5.5)    0.70
  **Sex (n and % women)**        23 (20.5%)    25 (16.1%)     9 (18%)       0.65
  **Total years of education**   15.7 (3.3)    15.6 (3.6)     15.4 (3.4)    0.88
  **MOCA score**                 27.4 (2.1)    27.4 (2.1)     27.3 (2.2)    0.93
  **IQ**                         118.9 (9.5)   118.7 (10.0)   117.9 (9.6)   0.82
  **BMI**                        25.6 (4.4)    26.6 (4.2)     26.8 (3.7)    0.1

Values denote mean (±Standard Deviation) or number of subjects, P-values refer to one-way ANOVAs (parametric data) and chi-square tests (categorical data).

Due to the significant effects of *UCP*2 polymorphisms on lifetime risk of mood disorders in men in this sample, we carried out two different analyses of the neuroimaging data. In the first analysis, all participants were included irrespective of sex and lifetime occurrence of mood disorder. There were no significant differences between *UCP2* haplotype groups for any of the neuroimaging measures investigated here. All non-thresholded statistical images for these analyses can be found on NeuroVault \[[@pone.0181392.ref036]\]: <http://neurovault.org/collections/IAGLVJEJ/>. In the second analysis, we only included male participants and investigated main effects of UCP2 haplotype group and lifetime occurrence of mood disorders and their interaction. Again, there was no significant main effect of *UCP2* haplotype group and no significant interaction between *UCP2* haplotype group and lifetime occurrence of mood disorders for any of the neuroimaging measures.

Discussion {#sec014}
==========

We set out to investigate possible effects of *UCP*2 polymorphisms on the risk of developing neurodegenerative disease but did not find significant effects in this sample. There are two possible explanations for this. On the one hand it is possible that the sample in this study was too small to detect significant effects and a larger study with more statistical power would be needed to rule this out. On the other hand it is possible that UCP2 polymorphisms do not play a role in the development of neurodegenerative disorders. This interpretation is backed up by the fact that *UCP2* polymorphisms have not been reported in genome-wide association studies (GWAS) that investigated genetic factors underlying risk of Alzheimer's disease (e.g. \[[@pone.0181392.ref037]\]) or Parkinson's disease (e.g. \[[@pone.0181392.ref038]\]). However, we observed a significant effect of *UCP2* polymorphisms on the occurrence of mood disorders in men in this sample. This effect was significant for both *UCP2* polymorphisms and showed a gene-dose effect in that those who carry two minor alleles had nearly threefold increased odds of lifetime occurrence of mood disorders and those with one minor allele a twofold elevated odds compared with those who are homozygote for the major alleles. While this is an intriguing finding, we could not replicate the effect in the larger Whitehall II sample. However, there are no data available for lifetime occurrence of mental health disorders for the larger sample, and we were only able to use proxy markers that will give an indication whether participants had a mood disorder when they were tested during the last 30 years. While *UCP2* polymorphisms have not been reported in GWAS for major depressive disorders (e.g. \[[@pone.0181392.ref039]\]) there are several reasons why it would still be worth following up on. First, patient data for GWAS often comes from those who have severe episodes of depression and are hospitalized. However, only very few participants included in this Whitehall II sub-study suffered from severe depression. In most cases they reported episodes of minor depression. Second, there are two important differences with regards to the age and sex distribution of the sample investigated here and those included in GWAS. The average age of participants in this study is around 70 years, which is different from many other samples that have a much lower average age, in most cases between 40 and 50 years (e.g. \[[@pone.0181392.ref040]\]). In addition, the sex distribution is different since around 80% of Whitehall II participants are men, whereas other samples have a much higher proportion of female patients from 50--80% (e.g. \[[@pone.0181392.ref040]\]). Therefore, *UCP2* polymorphisms might be genetic risk factors that affect lifetime occurrence of less severe mood disorders particularly in men. This would be a further indication of a link between mitochondrial (dys-)function and mood disorders \[[@pone.0181392.ref041]\]. However, it is a result that will need to be replicated independently.

To our knowledge this is the first study to investigate effects of *UCP2* polymorphisms on human brain structure and function using neuroimaging data. We did not find any significant effects of *UCP2* haplotype group on grey or white matter structure or resting-state functional connectivity. One interpretation is that *UCP2* polymorphisms do not affect brain structure or function. However, it is also possible that the sample investigated here was too small to find any significant effects, or that effects of *UCP2* polymorphisms on the brain are too subtle to be picked up by any of the neuroimaging measures here. Again, a larger study sample would be required to clarify these questions.

Conclusion {#sec015}
==========

In conclusion, we show in a sub-sample of the Whitehall II study that *UCP2* polymorphisms do not significantly affect grey or white matter structure or resting-state functional connectivity. An interesting effect of *UCP2* polymorphisms on lifetime occurrence of mood disorders requires independent replication.
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